Trials Sponsors Conditions Drugs Pricing

Conditions

Systemic Lupus Erythematosus

Keywords

Systemic Lupus Erythematosus in MartiniqueHydrolase and DNase activities

Outcome Measures

Primary Outcomes (1)

Frequency of hydrolase and DNase activities
Estimate the presence of a significant enzymatic activity by calculating the frequency of the hydrolase and DNase activities in lupus in Martinique(French west-indies)
2 years

Secondary Outcomes (1)

Association of disease activity and catalytic activity
2 years

Study Arms (2)

Cases

The "Case" group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2: * 30 patients with a quiescent lupus * 30 patients with an active lupus

Controles

The "Control" group is constituted by people coming to give blood to the French Blood Establishment of Martinique.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Cases are patients with Systemic Lupus Erythematosus treated at the Centre Hospitalier of Fort de France (Martinique): patients with a quiescent lupus and patients with an active lupus. Controles are people coming to donate blood samples at the French Blood Establishment of Martinique.

You may qualify if:

For patients:

Sponsors & Collaborators

University Hospital Center of Martinique
Otherlead

Study Sites (1)

Centre Hospitalier Universitaire de Fort de France

Fort de France, Martinique, 97261, France

Biospecimen

Retention: SAMPLES WITH DNA

* For the "case" means the research will be done on a blood sample of 7 ml, reclassified from treatement to research, collected from the blood sampling usually prescribed by doctors to treat the patient come to be diagnosed a lupus or for continuing care. * For the "control" means research will be done on a blood sample of 7 ml collected from people coming to donate blood at thethe French Blood Establishment of Martinique. The volume does not exceed the maximum amount allowed by French regulations for blood donation.

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

Christophe DELIGNY, MD
Service de Médecine Interne - Centre Hospitalier Universiatire de Fort de France
PRINCIPAL INVESTIGATOR

Enrollment

200 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 5, 2010

First Posted

July 7, 2010

Study Start

January 2012

Date type not reported

This date has not been verified as actual or estimated.

Catalytic Antibodies and Lupus in Martinique

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Cases

Controles

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Cases

Controles

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations